NCT06068101View on ClinicalTrials.gov

Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer

CompletedOBSERVATIONAL
Enrollment

274

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

December 1, 2022

Study Completion Date

August 1, 2023

Conditions
Thyroid Cancer, PapillaryPrimary Aldosteronism
Interventions
DIAGNOSTIC_TEST

Secreening test for primary aldosteronism and Confirmatory Testing

Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone \> or = 10 ng/dL and aldosterone to renin ratio \> or = 2 ng/dL/uUI/mL

Trial Locations (1)

01246-000

Ana Alice Wolf Maciel, São Paulo

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

Instituto do Cancer do Estado de São Paulo

OTHER

NCT06068101 - Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer | Biotech Hunter | Biotech Hunter